PIK3CA and urinary bladder cancer: PIK3CA-mutated bladder cancer patient-derived xenografts (PDXs) have a non-T-cell-inflamed phenotype, while the administration of BKM120, a pan PI3K inhibitor, induces immune activation and the response to PD-1 inhibitors [87].